E71.314
Muscle carnitine palmitoyltransferase deficiency
Clinical Classification Guidelines
Medical Intelligence & Overview
Muscle carnitine palmitoyltransferase deficiency (CPT deficiency) is a genetic disorder that impacts the body's ability to break down certain fats for energy. This condition specifically affects muscle cells, leading to episodes of muscle weakness and pain, particularly during periods of fasting or prolonged exercise. Understanding this condition helps patients recognize symptoms and seek proper management for minimizing episodes and maintaining quality of life.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the CPT enzyme responsible for transporting long-chain fatty acids into the mitochondria Inheritance pattern is typically autosomal recessive, meaning a person must inherit two defective copies of the gene to be affected Potential mutational variations impacting the enzyme's activity and stability
Key Symptoms: Muscle weakness or fatigue, especially after physical activity or fasting Episodes of muscle pain or cramping Rhabdomyolysis, which involves the breakdown of muscle tissue (rare but serious) Sometimes, symptoms may include elevated levels of muscle enzymes in blood tests Possible heart muscle involvement leading to arrhythmias in severe cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis often involves a combination of clinical evaluation and laboratory tests. Healthcare professionals may perform blood tests to measure muscle enzymes like creatine kinase. Genetic testing can confirm mutations in the CPT gene. Additionally, enzyme activity assays in muscle tissue or fibroblasts may be conducted. Sometimes, a muscle biopsy is performed to examine enzyme activity directly. Patient history, including episodes triggered by fasting, exercise, or illness, also provides important clues.
Treatment Protocols: Dietary modifications, such as high-carbohydrate, low-fat diets to reduce reliance on fatty acid oxidation Frequent, balanced meals to prevent fasting Supplementation with carnitine, although its benefits may vary Avoiding prolonged fasting and strenuous exercise Monitoring during illness or metabolic stress to prevent complications In severe cases, some may require hospitalization for intravenous glucose administration to provide immediate energy
Clinical Advice & FAQs
Billing Guidance
Is E71.314 a billable ICD-10 code?
Yes, E71.314 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E71.314?
Clinical documentation must specify the nature of Muscle carnitine palmitoyltransferase deficiency and any associated comorbidities for accurate reporting.
Cite this Clinical Reference